Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association.
about
MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activationMetabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndromePeroxisome Proliferator-Activated Receptor-γ Is Critical to Cardiac FibrosisThiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium RetentionAfter avandia: the use of antidiabetic drugs in patients with heart failureProbiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activationT2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding propertiesOn the metabolically active form of metaglidasen: improved synthesis and investigation of its peculiar activity on peroxisome proliferator-activated receptors and skeletal musclesEffects of PPARalpha on cardiac glucose metabolism: a transcriptional equivalent of the glucose-fatty acid cycle?Transcriptome alteration in the diabetic heart by rosiglitazone: implications for cardiovascular mortality.Piperine Attenuates Pathological Cardiac Fibrosis Via PPAR-γ/AKT Pathways.Betulinic acid is a PPARγ antagonist that improves glucose uptake, promotes osteogenesis and inhibits adipogenesis.Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes.Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity.Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factorsPulmonary hypertension and metabolic syndrome: Possible connection, PPARγ and Caveolin-1Pharmacogenetics of Anti-Diabetes Drugs.A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivityThe role of adiponectin in cancer: a review of current evidence.Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderlyThrap3 docks on phosphoserine 273 of PPARγ and controls diabetic gene programming.Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapySaxagliptin for type 2 diabetesRisk management in the treatment of type 2 diabetes with pioglitazoneEvolution of peroxisome proliferator-activated receptor agonists.Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes.Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylationIdentification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis.Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysisPeroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease.Rosiglitazone plus metformin: combination therapy for Type 2 diabetes.Short-term and long-term effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with renal impairment: a meta-analysis of randomized controlled trials.Selective targeting of PPARγ by the natural product chelerythrine with a unique binding mode and improved antidiabetic potency.Mortality experience of a low-income population with young-onset diabetes.Update on Safety Issues Related to Antihyperglycemic TherapyMetabolic Syndrome Abolishes Glucagon-Like Peptide 1 Receptor Agonist Stimulation of SERCA in Coronary Smooth MuscleA double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetes.
P2860
Q21342745-397D3A77-01B5-42A0-A461-606F585D01D2Q24816197-0F7228C6-77C3-4468-996E-30421EF837FBQ26746998-FB5D332C-F2CF-44A9-9B2E-3EBDFB2898BEQ26851905-68D06FE3-5EAC-4568-BADF-A92676204D7EQ27021166-D92FAAD6-83D9-4B40-AA12-3646BA5D979BQ27327276-2AB23237-6F83-494C-BADF-6235FD45E86AQ27649827-877E6503-4085-4216-8BCD-3C9BC27C58BFQ27697692-7FE62F4D-C288-48FE-99D3-213E242B1929Q30353176-F7EA9F8D-0657-458A-B5DE-D2D682598B16Q33354126-2436F6A5-39E1-4C62-82AE-E1C0A5AE0298Q33603596-187F61B3-BD07-41F2-94D9-020920EF9F80Q33916179-98DAD568-8107-4031-A9BD-1A0B6AA69C8DQ33932712-50B7F9B0-6A50-4ED0-8F09-D01332268275Q33961458-20B36C4B-8E00-44C1-A5EE-FED1519E5DDDQ34056132-4942E5A7-2032-4153-B02D-649B3660A29BQ34068749-168FA5E6-A533-493C-B404-D65EA923C1D6Q34133889-B4003A4E-F63A-487A-A73D-1C1D5F0085B4Q34178976-6385101B-F7B0-43E5-A6B3-836735398FF6Q34181995-8A07FAA0-0D6F-4B3E-A4A3-5E788F1D2900Q34249161-0D369D37-41AA-4861-AF79-2D4555A9CF71Q34271986-55909398-52D1-412F-A1E2-E4302173354FQ34315432-6A9F3C3B-FB2A-4352-86E9-D08ADAD24128Q34386587-AE821CA6-0FF9-4EDC-A1BB-5E0AECFC6DEEQ34430709-20950ACB-A304-459B-8842-FB38CDF33AAEQ34449858-94BAC499-69B4-49FE-B196-A7776F1B8465Q34620486-A781F8ED-B510-46F6-9D4B-00D9E000D13FQ34620706-45986849-386D-4686-8160-1929465EFFF8Q34630829-0D4E555A-68D6-4742-9FBE-A9692C2C5797Q35214420-47C4BC92-51D5-42A3-8D2A-B5D6406E88F3Q35230678-A9269E1A-C4C0-4907-A8E2-24BC416EDE72Q35237706-49CD6FE7-5CC1-4A00-97E3-88E0A9677A01Q35382193-C21D10B8-9175-4137-A205-04CFE5E2855FQ35636191-C8B5BD95-C0B1-4DEF-AB3E-532441F2599AQ35784092-4B8EAA11-4264-4B2C-BB1A-D77AA5F34E82Q35798155-C9EDE717-EFE7-4381-93C0-97609E79C66FQ35860302-EE1B3DF6-B821-4A2D-A817-BF378D6C4B45Q35878985-07C1D142-506F-47DB-BD15-7F1F55CBF5A5Q35910429-10032F65-3BB8-45AD-8CA0-EDA257AF3418Q35973848-99F89267-9341-41E3-887C-AA414456C1D9Q35987436-CDD084DE-8ACF-4EC6-B7D1-E17D189FC09E
P2860
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Thiazolidinedione use, fluid r ...... American Diabetes Association.
@ast
Thiazolidinedione use, fluid r ...... American Diabetes Association.
@en
type
label
Thiazolidinedione use, fluid r ...... American Diabetes Association.
@ast
Thiazolidinedione use, fluid r ...... American Diabetes Association.
@en
prefLabel
Thiazolidinedione use, fluid r ...... American Diabetes Association.
@ast
Thiazolidinedione use, fluid r ...... American Diabetes Association.
@en
P2093
P356
P1433
P1476
Thiazolidinedione use, fluid r ...... American Diabetes Association.
@en
P2093
Clay F Semenkovich
Daniel Porte
David Bell
Edward S Horton
Lawrence H Young
Martin Le Winter
Richard Kahn
Richard W Nesto
Robert O Bonow
Scott M Grundy
P304
P356
10.2337/DIACARE.27.1.256
P407
P577
2004-01-01T00:00:00Z